"One DEA Schedule I laboratory registration approved. FDA INDs granted. Orphan Drug Designation awarded. Yet the cultivation application remains unresolved...
IMA401 achieved deep and durable responses in various indications, including melanoma and head and neck cancer, with an initial promising...
Compared with patients receiving hormone therapy alone, patients were nine times more likely to have little to no cancer remaining...
Results simultaneously published in The New England Journal of MedicineREDWOOD CITY, Calif., May 31, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines,...
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma Brenetafusp monotherapy resulted in a...
WOBURN, Mass., May 31, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development...
SlimTide Prebiotic Probiotic Formula for Gut Health and Metabolic Support: Ingredients, Side Effects, Dosage, and 60-Day Guarantee BreakdownLargo, FL, May...
CHICAGO, May 31, 2026 (GLOBE NEWSWIRE) -- NeuExcell Therapeutics today announced that Dr. Yulun Huang will present the first-in-human clinical...
Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with Pluvicto plus standard of care (ARPI...
ORION CORPORATION PRESS RELEASE 30 MAY 2026 at 21:30 EEST Orion Pharma announces first results from Phase 1/2 TEADES trial with...
TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and...
First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1 expression levels and subtypes, highlighting its potential...
Exploratory analysis showed favorable patient-reported quality of life outcomes and delayed time to deterioration in patients receiving ¹⁷⁷Lu-edotreotideData build upon...
– Post hoc analysis from pivotal Launch-HTN trial shows statistically significant and clinically meaningful reductions in blood pressure in participants...
– Updated data across two dose levels of 200 mW/cm and 400 mW/cm in LA-PDAC trial show 71% (5/7) patients...
JUDGE McFADDEN SAID MMJ HAS "NO PRODUCT." THE RECORD SAYS OTHERWISE.How Can a Company With FDA INDs, Orphan Drug Designation,...
Designed around the “Bring On The Mess” philosophy, the new wipes are larger than most leading brands by sheet dimensions,...
Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of...
WOBURN, Mass., May 30, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development...
One-time infusion of IMA203CD8 PRAME cell therapy in the ongoing Phase 1 dose escalation/dose expansion trial achieved anti-tumor activity in...